Since we found a clear correlation between bFGF and CD13 expression and invasiveness of melanoma cells, the incorporation of bestatin in a clinical trial in stage II melanoma patients should be considered with the aim of preventing the development of metastases and to improve survival. This evidence concerns the gene FGF2 and melanoma.